Semaglutide cost in 2026
Semaglutide pricing across Ozempic, Wegovy, direct-pay and compounded pathways.
Brand GLP-1 prices collapsed in late 2025 and most comparison pages have not caught up. As of July 12, 2026, brand Zepbound is $299–$449/month through LillyDirect, brand Wegovy is $349 through NovoCare (the oral Wegovy tablet is $149), and either drops to about $25 with commercial coverage that includes it. Retail list prices are $1,086 (Zepbound) and $1,349 (Wegovy). Compounded programs advertise $99–$299 — but they are not FDA-approved and their legal basis narrowed sharply in 2025. All brand figures here are verified against manufacturer sources.
Cost by pathway
Bars use the low end of each pathway's range. Compounded and all-inclusive cash options sit far below retail brand pricing — the tradeoff is FDA-approval status.
| Pathway | Typical cost | Notes | Status |
|---|---|---|---|
| Wegovy tablets (oral semaglutide, brand) | $149/month | NovoCare; 1.5mg & 4mg. 4mg at this price to Aug 31, 2026 | Verified |
| Zepbound 2.5 mg (brand, LillyDirect) | $299/month | Starting dose; no refill-window condition | Verified |
| Wegovy standard (brand, NovoCare) | $349/month | Cut from $499 in Nov 2025. $199 first 2 fills for new patients | Verified |
| Ozempic standard (brand, NovoCare) | $349/month | 0.25-1mg; 2mg is $499 | Verified |
| Zepbound 5 mg (brand, LillyDirect) | $399/month | No refill-window condition | Verified |
| Zepbound 7.5-15 mg (brand, LillyDirect) | $449/month | ONLY if refilled within 45 days of last delivery | Verified |
| Zepbound 10-15 mg — 45-day window missed | $699/month | The penalty rate. A $250/month mistake | Verified |
| Brand + commercial insurance + savings card | as low as $25/month | Zepbound or Wegovy, if your plan covers it | Verified |
| Medicare GLP-1 Bridge (Wegovy) | $50/month | Eligible Part D beneficiaries, Jul 1 2026 - Dec 31 2027 | Verified |
| Retail Zepbound pen (list price) | $1,086/month | What you pay with no program at all | Verified |
| Retail Wegovy (list price) | $1,349/month | What you pay with no program at all | Verified |
| Compounded GLP-1 (telehealth) | $110-$399/month | NOT FDA-approved. Legal basis narrowed sharply in 2025 | Verified |
We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.
Every fee that can be attached to a GLP-1 programme
An advertised price is a headline. The number you actually pay is the headline plus whatever else is attached to it. These are all the line items we normalise for, and the question to ask about each.
| Line item | What to ask | How often it bites |
|---|---|---|
| Advertised starting price | Is this a first-month or introductory rate? | Very often — TrimRx, MEDVi, Noom, Eden all advertise intro rates |
| Ongoing price | What do I pay in month two? | This is the number that matters |
| Membership fee | Is it required, and is it billed separately? | Very often — Eden, Mochi, Hims, Hers, Ro, PlushCare |
| Consultation fee | Is the initial visit billed separately? | Sometimes — PlushCare charges $129 initially |
| Laboratory fee | Are baseline labs included or billed to me? | Varies; often unstated until intake |
| Shipping | Included? Expedited? Cold-chain? | Usually included; confirm it |
| Supplies | Are syringes, needles and sharps disposal included? | Usually included on all-inclusive plans |
| Dose-based increase | What do I pay at the highest dose you cover? | Material — MEDVi goes $399 to $499; Shed and Oak escalate |
| Dose ceiling / cap | Is there a maximum dose on this plan? | Material — Noom's $199 plan caps at 0.6mg |
| Upfront payment | How much do I pay today to get the advertised rate? | Found's $169 requires roughly $2,028 up front |
| Renewal price | Does the price change when the plan renews? | Frequently unstated — get it in writing |
| Cancellation terms | If I stop in month three of twelve, what happens to my money? | The most-forgotten question in the category |
The three that cost people the most money, in our experience, are the ones in bold: the intro rate they mistook for the real rate, the dose-based increase they did not model, and the cancellation terms they did not read. None of those are hidden. All of them are simply not asked about.
A worked example
Two programmes. One advertises $179. The other advertises $186. Which is cheaper?
| Programme A (advertised $179) | Programme B (advertised $186) | |
|---|---|---|
| Month 1 | $179 (intro rate) | $186 |
| Months 2-12 (ongoing rate) | $299 × 11 = $3,289 | $186 × 11 = $2,046 |
| Membership (if any) | $0 | $0 |
| Dose-based increase | None stated | None — flat at every dose |
| Twelve-month total | $3,468 | $2,232 |
| Effective monthly | $289 | $186 |
Programme A advertises a lower number and costs $1,236 more per year. This is not a hypothetical: the figures are TrimRx's advertised semaglutide rate against NexLife's standard tirzepatide plan. The advertised prices are seven dollars apart. The real prices are over twelve hundred dollars apart.
Brand pricing, verified against the manufacturers
These are the numbers we can stand behind, because they come from Lilly's and Novo's own pricing pages rather than from a comparison site quoting another comparison site.
| Dose | Self-pay price | Condition |
|---|---|---|
| 2.5 mg (starting dose) | $299/mo | No refill-window condition |
| 5 mg | $399/mo | No refill-window condition |
| 7.5 mg | $449/mo | Only if refilled within 45 days — otherwise $499 |
| 10 mg | $449/mo | Only if refilled within 45 days — otherwise $699 |
| 12.5 mg | $449/mo | Only if refilled within 45 days — otherwise $699 |
| 15 mg (maintenance) | $449/mo | Only if refilled within 45 days — otherwise $699 |
| Dose | Price inside window | Price outside window | Penalty |
|---|---|---|---|
| 7.5 mg | $449 | $499 | +$50 |
| 10 mg | $449 | $699 | +$250 |
| 12.5 mg | $449 | $699 | +$250 |
| 15 mg | $449 | $699 | +$250 |
Prices at 7.5 mg and above hold only if you refill within 45 days of the previous delivery. Outside that window the same doses cost $499-$699.
| Product / dose | Self-pay price | Notes |
|---|---|---|
| 0.25 mg / 0.5 mg (first 2 fills, new patients) | $199/mo | Introductory offer through Dec 31, 2026 |
| 0.25–2.4 mg (standard, after intro) | $349/mo | Cut from $499 in November 2025 |
| Wegovy HD 7.2 mg | $399/mo | |
| Wegovy tablets 1.5 mg / 4 mg (oral) | $149/mo | 4 mg at this price through Aug 31, 2026, then $199 |
The finding that changes the decision
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
Brand figures are verified against manufacturer pricing pages. The compounded figure is the lowest advertised rate we have seen and is unverified. Note where the brand oral tablet sits.
How we normalize total cost
Advertised starter prices are not comparable on their own. We calculate a normalized monthly cost that adds required membership, consultation, laboratory, shipping and administrative fees, divided by covered months, and we compute it separately for the initial month, ongoing month, and 3-, 6- and 12-month totals. See the full price-verification methodology.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
Why is compounded tirzepatide so much cheaper than Zepbound?
Compounded preparations skip brand manufacturing, packaging and FDA-approval overhead. They are also not FDA-approved and are not quality-verified by the agency before marketing — a real tradeoff, not a free discount.
Can I get GLP-1 medication without insurance?
Yes — cash-pay telehealth and manufacturer direct-pay vial programs exist. Whether compounded options are lawfully available depends on current FDA compounding rules, which have tightened.
What is the cheapest legitimate option?
The lowest advertised starter price in our set is $133/month, but the lowest verified all-inclusive cost after fees was NexLife at $147/month. See our cheapest tirzepatide guide.
Sources
- Eli Lilly — LillyDirect Zepbound pricing page and Zepbound Self Pay Journey Program terms (CMAT-05333, 05/2026), captured July 12, 2026.
- Eli Lilly — press release, "Lilly lowers the price of Zepbound single-dose vials," December 1, 2025.
- Novo Nordisk — NovoCare Pharmacy pricing pages and Wegovy Price Guide, captured July 12, 2026.
- Novo Nordisk — press release, introductory self-pay offer for Wegovy and Ozempic, November 17, 2025.
- U.S. Food and Drug Administration — compounding status and enforcement history.
- Our normalization methodology.